Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;24(11):687-695.
doi: 10.1007/s11920-022-01372-x. Epub 2022 Oct 1.

Selective Serotonin Reuptake Inhibitors (SSRIs) in Pregnancy: An Updated Review on Risks to Mother, Fetus, and Child

Lindsay G Lebin  1 , Andrew M Novick  2
Affiliations
Review

Selective Serotonin Reuptake Inhibitors (SSRIs) in Pregnancy: An Updated Review on Risks to Mother, Fetus, and Child

Lindsay G Lebin et al. Curr Psychiatry Rep. 2022 Nov.

Abstract

Purpose of review: To provide an updated summary and appraisal of work from 2019 to 2022 examining risks of selective serotonin reuptake inhibitor (SSRI) use in pregnancy.

Recent findings: Perinatal SSRI exposure does not increase risk of major malformations or gestational diabetes after accounting for underlying maternal illness. SSRIs are associated with small increase in risk of pre-eclampsia, postpartum hemorrhage, preterm delivery, persistent pulmonary hypertension of the newborn, and neonatal intensive care unit admissions, though absolute risk of these outcomes is low. While data suggests no increased risk of neurodevelopmental disorders in offspring, mixed evidence indicates increased risk of adverse cognitive outcomes and affective disorders. Recent evidence suggest low absolute risk of clinically relevant negative outcomes with perinatal SSRI exposure when compared to untreated perinatal depression. However, study design and ability to control for confounding remains an ongoing research challenge, highlighting need for ongoing rigorous study design and analysis.

Keywords: Antidepressant; Mood disorders; Perinatal; Pregnancy; Psychopharmacology; SSRI.

PubMed Disclaimer

Conflict of interest statement

Competing Interests The authors declare no competing interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005;106(5 Pt 1):1071–83. 10.1097/01.AOG.0000183597.31630.db. - DOI - PubMed
    1. Force UPST. Interventions to prevent perinatal depression: US Preventive Services Task Force recommendation statement. JAMA. 2019;321(6):580–7. 10.1001/jama.2019.0007. - DOI - PubMed
    1. Molenaar NM, Bais B, Lambregtse-van den Berg MP, Mulder CL, Howell EA, Fox NS, et al. The international prevalence of antidepressant use before, during, and after pregnancy: a systematic review and meta-analysis of timing, type of prescriptions and geographical variability. J Affect Disord. 2020;264:82–9. 10.1016/j.jad.2019.12.014. - DOI - PubMed
    1. Andrade SE, Reichman ME, Mott K, Pitts M, Kieswetter C, Dinatale M, et al. Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration’s Mini-Sentinel program. Arch Women’s Ment Health. 2016;19(6):969–77. 10.1007/s00737-016-0637-1. - DOI - PubMed
    1. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008;198(2):194. e1–5. 10.1016/j.ajog.2007.07.036. - DOI - PubMed

Publication types

Substances